Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks

CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead of future pandemics, released its Antiviral Clinical and Preclinical Development Landscape. In this third edition report, the Alliance adds a list of preclinical antiviral compounds to its ongoing analysis of clinical antiviral compounds in development that target the 13 viral families identified1 as having potential to result in a pandemic which now includes mpox.

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here